was one of Monday's winners, a day after the company reported positive results from a clinical trial of its Xience drug-coated stent, clearing an important hurdle on the path to Food and Drug Administration approval. Abbott was recently adding $2.07, or 3.8%, to $55.93.
Meanwhile, shares of
slid more than 5% after the performance of Abbott's Xience stent was deemed superior to that of Boston Scientific's Taxus stent in a study. Lately, the stock was off 77 cents, or 5.1%, to $14.45.
jumped after the company reported positive safety and efficacy data on Sunday from a phase I study of its adult stem-cell therapy, Provacel, in patients with heart disease. Osiris was higher by $2, or 11.2%, at $19.90.
were easing after the company announced a joint venture with
that will combine the cholesterol drug Lipitor with Zetia. Merck was losing 28 cents, or 0.6%, to $44.17.
Meanwhile, Schering-Plough was adding 52 cents, or 2.1%, to $25.14.
, which holds the patent for Lipitor until 2010, was recently down 16 cents, or 0.6%, to $25.50.
soared 51.3% after
said it will acquire the company.
was rising 10.6% to $44.30.
dropped 20% to $6.86 on a downgrade by Deutsche Securities.
was sliding 1.8% to $82.16.
was down 1.3% to $49.26.